{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-26-000003","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2026-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.902072+00:00","generated_at":"2026-05-16T03:45:38.376027+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Gilead Q4/FY2025: revenue up 5% to $7.9B Q4, full-year EPS $6.78; guides 2026 sales $29.6-30B","bullets":["Q4 GAAP diluted EPS $1.74 vs $1.42 YoY; non-GAAP diluted EPS $1.86 vs $1.90.","Q4 product sales up 5% to $7.9B; HIV sales up 6% to $5.8B; Biktarvy $4.0B (+5%).","Full year 2025 total revenues $29.4B (+2%); product sales ex-Veklury $28.0B (+4%).","Full year GAAP diluted EPS $6.78 vs $0.38; non-GAAP $8.15 vs $4.62.","FY2026 guidance: product sales $29.6-30B, non-GAAP diluted EPS $8.45-8.85."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-26-000003","json":"https://secwatch.observer/filing/0000882095-26-000003.json","markdown":"https://secwatch.observer/filing/0000882095-26-000003.md","text":"https://secwatch.observer/filing/0000882095-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000003/0000882095-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000003/gild-20260210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:45:38.376027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}